Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice

Figure 1

Overall survival according to bevacizumab treatment at first glioblastoma recurrence. Sample sizes were n = 24 for patients who received bevacizumab and other agents (BVZ and other), n = 19 for patients who received bevacizumab alone (BVZ alone), n = 22 for patients who received only non-bevacizumab treatment (Other), and n = 32 for patients who received no treatment (None). The distance spanned by the bottom and top of each box represents the interquartile range, the enclosed line represents the percentile, and the whiskers stretch to the data point that is not > 1.5 times the interquartile range from the box. Data points that fell outside the range of the whiskers were represented by small, open circles. P = 0.0000033 and P = 0.00015 for paired comparisons between treatment groups using Wilcoxon rank sum test. Abbreviation: BVZ, bevacizumab.